drugset / Trial / NCT00649844

A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs

NCT00649844

Phase 3 Completed 147 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment

Timeline

Start
2003-01
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clozapine Other / unclassified 250 mg
Comparator Clozapine Other / unclassified 600 mg
Subject Ziprasidone Small molecule 80 mg
Subject Ziprasidone Small molecule 160 mg

Indications